Metabolic dysfunction-associated steatohepatitis

This trial tests an experimental oral drug called resmetirom in children aged 6 to 17 with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. The study aims to evaluate the drug's safety, how the body processes it, and its effects on the liver. Participan…

This trial tests whether replacing some of the usual diet with navy beans — without changing total calories — is a practical and acceptable way to help manage metabolic dysfunction-associated steatotic liver disease (MASLD) in adults with intermediate-stage liver fibrosis. Forty …

This trial tests an experimental gene therapy called VV-14303 for people with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity and diabetes. The therapy uses a harmless virus to deliver a protein (FGF21) that may improve liver h…

This study tests whether a 12-week program combining a weekly injection of mazdutide (a drug that targets gut hormones) with lifestyle counseling can quickly reduce liver fat in overweight or obese people who want to donate part of their liver but are temporarily disqualified due…

This study tests whether adding a Mediterranean-style meal delivery program to resmetirom therapy improves liver health more than resmetirom alone. It involves 120 adults with non-cirrhotic MASH who are starting resmetirom. Participants either receive the drug plus 10 medically t…

This clinical trial tests two experimental injections, HRS-4729 and HRS9531, in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity. The study involves 160 participants who receive either the drug or a placebo for 52 we…

This Phase 3 trial tests whether the drug HSK31679 can safely improve liver health in 400 adults with MASH, a serious fatty liver disease. Participants will take either the drug or a placebo daily for about a year. The main goals are to see if the drug can reverse liver inflammat…

This study tests an experimental drug called ALN-CIDEB in 150 adults with MASH, a serious liver disease involving fat buildup and scarring. The goal is to see if the drug can reduce liver fat, injury, and scarring compared to a placebo. Participants will receive either the drug o…

This Phase 2 trial tests a new drug called QL2401 in 132 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate liver scarring. Participants receive weekly injections of either QL2401 or a placebo for 48 weeks. The main goal is to see if the drug reduces…

This study looks at whether combining a probiotic supplement with resistance exercise can help people with metabolic fatty liver disease (MAFLD/NAFLD). Researchers will measure changes in liver fat using MRI over 12 weeks. The goal is to find out which patients benefit most based…

This study tests a new drug called SNP-610 for people with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. About 80 adults will receive either the drug or a placebo for 3 months. The main goal is to see if SNP-610 lowers liver enzyme levels and reduces liver …

This early-stage study tests a new oral drug called ACT500 in 24 adults with fatty liver disease (MASLD). The main goal is to check safety and how the drug moves through the body. Participants take one pill daily in different dose groups. The study does not aim to cure the diseas…

This study tests a temporary device placed in the upper small intestine to help control type 2 diabetes and obesity. The implant stays for 6 months and is then removed. Researchers will check if it lowers blood sugar (HbA1c), helps with weight loss, and improves liver health in p…

This study tests whether betaine, a natural substance found in the body, can reduce liver injury in people with MASH (a serious fatty liver disease). Seventy participants will take either betaine or placebo pills for 24 weeks, with follow-up for another 24 weeks. The main goal is…

This study tests two blood products used to control bleeding during liver transplant surgery. It compares a newer product, Intercept Fibrinogen Complex, to standard cryoprecipitate. The goal is to see if the newer product works as well or better at stopping bleeding. The study wi…

This study tests whether empagliflozin (a diabetes drug) works better than statins for treating non-alcoholic fatty liver disease (NAFLD) and its more severe form, NASH. 400 obese, diabetic adults with NAFLD/NASH will take one of five drug combinations daily for 3 months. Researc…

This study tests whether adding a traditional Chinese medicine granule (Huazhi Rougan) to standard antibiotics can better treat both H. pylori infection and metabolic-associated fatty liver disease (MASH). About 286 adults with both conditions will receive either the herbal granu…

This study tests a near-infrared spectroscopy device that scans the liver with light to diagnose and measure fatty liver disease. Researchers aim to see if it can accurately detect fat levels above 5% and 30%, which are important for liver transplant decisions. The study will inc…

This study looks at how bariatric surgery affects the liver's energy processing in people with obesity and fatty liver disease. Researchers will use safe, non-radioactive tracer infusions and MRI scans before, during, and six months after surgery to measure changes in liver metab…

This study tests new MRI techniques to measure blood flow and tissue details in the liver. Researchers will scan 110 people, including healthy volunteers and those with chronic liver disease or fibrosis, to see if these scans can reliably detect liver damage. The goal is to devel…

This French study will collect medical data and biological samples from 800 people with autoimmune liver diseases. Researchers hope to identify new markers that explain why some patients respond well to treatment while others do not. The goal is to better understand the immune me…

This study looks at how a 12-week exercise program (strength and aerobic training twice a week) affects liver fat, inflammation, and scarring in people with metabolic fatty liver disease. It compares results between older adults (70+) and middle-aged adults (40-60), as well as be…

This study will screen up to 10,000 adults aged 18-75 who are overweight or have metabolic issues like high blood sugar or cholesterol. Researchers will use questionnaires, blood tests, and liver ultrasounds to find out how common fatty liver disease is and what factors increase …

This early-stage study tests the safety and tolerability of a new drug called QL2401 in 70 healthy Chinese adults aged 18 to 45. Participants receive either the drug or a placebo to see how the body handles it. The goal is to gather initial safety data before testing in people wi…

This study looks at stored liver biopsy samples from 30 people with MASH (a fatty liver disease) to see if a protein test can predict who will develop liver cancer within 15 years. Half of the participants later got liver cancer, and half did not. Researchers will compare the pro…

This study will compare a new handheld device to the standard iLivTouch system for measuring liver stiffness and fat in 224 adults with chronic liver disease. Participants will be tested with both devices while lying down and sitting. The goal is to see if the handheld device is …